| 製品名 | Sunifiram |
| 同義語 | DM-235; DM235; 1-Benzoyl-4-propanoylpiperazine; 1-(4-Benzoylpiperazin-1-yl)propan-1-one; 1-Benzoyl-4-(1-oxopropyl)piperazine |
| CAS番号 | 314728-85-3 |
| 分子式 | C₁₄H₁₈N₂O₂ |
| 分子量 | 246.30 g/mol |
| 外観 | 白色からオフホワイトの結晶性粉末 |
| 分析（HPLC） | ≥ 99.0% |
| 融点 | 86–89°C |
| 乾燥減量 | ≤ 0.5% |
| 焼失残渣 | ≤ 0.1% |
| 重金属 | 10 ppm以下 |
| ストレージ | 涼しく、乾燥した、密閉された、光を遮断した場所 |
| 賞味期限 | 36ヶ月 |
お困りですか？ 弊社チームまでお問い合わせください
Sunifiram (developmental code DM-235) is a 強力な向知性化合物 belonging to the piperazine class.
It was developed as a next-generation cognitive enhancer with significantly higher potency than the classic racetam family (piracetam, aniracetam).
Sunifiram is structurally distinct from racetams but shares similar glutamatergic mechanisms.
Sunifiram is estimated to be ピラセタムよりも約1,000倍も強力 動物モデルにおいて。.
It acts as a positive allosteric modulator of AMPA receptors and may also influence nicotinic acetylcholine receptors (nAChRs).
Unlike many racetams, sunifiram does not require metabolic activation.
Sunifiram Nootropic Supplement
Sunifiram was developed by researchers at the University of Florence, Italy, as part of a series of potent ampakine-like compounds. Along with Unifiram (DM-232), it was designed to overcome the low potency limitations of traditional racetams. Preclinical studies demonstrated cognitive-enhancing effects at microgram-per-kilogram doses—orders of magnitude lower than piracetam (which requires milligram-per-kilogram doses).
Sunifiram exerts its effects primarily through glutamatergic modulation:
| パスウェイ | Proposed Mechanism | Cognitive Effect |
|---|---|---|
| AMPA receptor positive allosteric modulation | Enhances glutamate-induced currents; increases synaptic plasticity | Memory consolidation, learning, attention |
| Nicotinic acetylcholine receptor (nAChR) modulation | May influence α7 nAChR subtypes (preliminary) | Focus, working memory |
| Cholinergic enhancement | Indirect (via glutamatergic-cholinergic interaction) | Learning, memory |
| 用途 | 説明 | エンドユーザー |
|---|---|---|
| AMPA receptor research | Studying positive allosteric modulation of AMPA receptors | Academic neuroscience, pharmacology labs |
| Cognitive enhancement studies | In vitro and animal models of memory, learning, attention | Behavioral neuroscience research |
| Scopolamine-induced amnesia models | Reversal of cholinergic deficit (Alzheimer’s research models) | Neuropharmacology, drug discovery |
| Comparative nootropic research | Potency comparisons with racetams and other ampakines | 医薬品の研究開発 |
| Research Focus | 用途 |
|---|---|
| Piperazine vs. pyrrolidone scaffolds | Comparing structural requirements for AMPA modulation |
| Derivative synthesis | Developing novel sunifiram analogs with improved properties |
| Receptor binding studies | Characterizing AMPA receptor subtype selectivity |
| 用途 | 説明 |
|---|---|
| Reference standard | HPLC, LC-MS method development |
| Impurity profiling | For custom synthesis quality control |
| Stability studies | Forced degradation, long-term stability |
リブバイオ株式会社. is a GMP-certified supplier of high-purity Sunifiram for research and development applications.
供給能力：
分析法（HPLC）： ≥99.0%
フォーム： 結晶性粉末
月間処理能力： 5+ kg
大量注文： 1g – 5kg
リードタイム： 3～5日（サンプル）、10～15日（大量注文）
ドキュメント： COA, MSDS,HNMR, HPLC chromatogram, stability data
品質保証：
UV検出を用いたHPLCによる純度測定
残留溶媒の試験結果（USP に適合）
検査対象の重金属（ICP-MS法）
構造確認（ご要望に応じてNMR分析）
📧 お問い合わせ： info@lyvbio.com
| パラメータ | 仕様 | 試験方法 |
|---|---|---|
| 分析（HPLC） | ≥ 99.0% | HPLC-UV (254 nm) |
| 外観 | 白色からオフホワイトの結晶性粉末 | ビジュアル |
| 識別 | HPLC保持時間、NMR（ご要望に応じて） | HPLC／NMR |
| 融点 | 86–89°C | USP |
| 乾燥減量 | ≤ 0.5% | USP |
| 焼失残渣 | ≤ 0.1% | USP |
| 重金属 | Pb ≤ 10 ppm；As ≤ 2 ppm；Cd ≤ 1 ppm；Hg ≤ 0.1 ppm | ICP-MS |
| 関連物質 | 単一不純物 ≤ 0.5%；合計 ≤ 1.0% | HPLC-UV |
| 残留溶剤 | USP について | GC |
| 粒子径 | 95%～80メッシュ | ふるい分析 |
Q: Is Sunifiram the same as Piracetam or Aniracetam?
A: No. Sunifiram is a structurally distinct piperazine derivative, not a racetam. It is estimated to be approximately 1,000 times more potent than piracetam in animal models.
Q: Is Sunifiram FDA-approved for medical use?
A: いいえ。. Sunifiram has no approved medical use in any major market. It is a research chemical for laboratory use only. No human clinical trials have been published.
Q: What is the difference between Sunifiram and Unifiram (DM-232)?
A: Both are piperazine derivatives developed by the same research group. They have similar potency (~1,000x piracetam) but different chemical structures (different substituents on the piperazine ring). Unifiram is CAS 219694-40-3.
Q: What is the mechanism of action of Sunifiram?
A: Sunifiram is believed to act as a positive allosteric modulator of AMPA receptors (an ampakine). It may also influence nicotinic acetylcholine receptors. Detailed receptor binding studies are limited.
Q：動物実験における実効線量の範囲はどのくらいですか？
A: Published studies report cognitive-enhancing effects at 0.01–0.1 mg/kg (oral) in rodents—approximately 1,000 times more potent than piracetam.
Q: Are there human clinical trials for Sunifiram?
A: いいえ。. No human clinical trials have been published. Sunifiram is a research chemical only.
📧 メールアドレス： info@lyvbio.com
🌐 ウェブサイト： https://www.lyvbio.com
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese